Cost-Effectiveness of the Aerobika® Oscillating Positive Expiratory Pressure Device in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Canada

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left"> </td><td class="align_center">Aerobika® device</td><td class="align_center">No PEP/OPEP therapy</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">Total direct medical cost</td><td class="align_center">$6,712.19</td><td class="align_center">$8,835.71</td></tr><tr><td class="align_left">Total QALYs</td><td class="align_center">0.63</td><td class="align_center">0.53</td></tr><tr><td class="align_left">Cost savings</td><td class="align_center" colspan="2">$2,123.52</td></tr><tr><td class="align_left">QALY gained</td><td class="align_center" colspan="2">0.1</td></tr><tr><td class="align_left">Incremental cost-effectiveness ratio (ICER)</td><td class="align_center" colspan="2">Aerobika® device is the dominant strategy</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Scenario analysis results: incremental cost and incremental effect.</div>

Canadian Respiratory Journal

tab3

Table 3

Table 3: Cost-Effectiveness of the Aerobika® Oscillating Positive Expiratory Pressure Device in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Canada 

Table 3 | Cost-Effectiveness of the Aerobika® Oscillating Positive Expiratory Pressure Device in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Canada 